Revised Manuscript 3

Submission date: 07-Jun-2023 11:21AM (UTC+0900) Submission ID: 1857751264 File name: Revised_Manuscript_3.docx (34.46K) Word count: 2493 Character count: 14109

Abstract

Background: The prevalence of atherosclerotic cardiovascular disease appears to be reduced, according to a large body of research, by lowering blood levels of the ratio of low-density lipoprotein cholesterol (LDL-C)/ high-density lipoprotein cholesterol (HDL-C), triglyceride (TG)/HDL-C, and LDL-C.

Objective: The objective of the investigation was to determine the safety and endurance of policosanol (20 mg/d), as well as its efficacy in healthy individuals. Two parallel groups in this randomized, double-blind, placebo-controlled human experiment received either a policosanol (20 mg/d) or a placebo for eight weeks. 80 people were randomly assigned, with a mean (SD) age (years) of 42.61 (13.51), a mean (SD) BMI (kg/m²) of 24.53 (3.57), a mean (SD) weight (kg) of 66.71 (14.30), and a mean (SD) height (cm) of 164.21. (7.99).

Results: At 8 weeks, when compared to the baseline group, the policosanol (20 mg/d) batch displayed considerably greater LDL-C (-4.87 ± 11.30 mg/dL; p = 0.014), total cholesterol (- $6.82 \pm 14.32 \text{ mg/dL}$; p = 0.007), triglyceride (-9.37 ± 19.27 mg/dL; p = 0.008), non HDL-C reductions (-10.32 ± 13.75 mg/dL; p = 0.0001), and significantly greater augmentation of HDL-C (3.50 ± 4.55 mg/dL; p = 0.010). Policosanol (20 mg/d) treatment also significantly reducing the serum levels of TC/HDL-C (p = 0.0001) and LDL-C/HDL-C (p = 0.0002), triglyceride/HDL-C (p = 0.001), and T-cholesterol-HDL-C (p = 0.0001) ratios.

Conclusion: In humans, policosanol delivery resulted in a lowering of LDL-C levels and an improvement in other lipid markers, demonstrating the product potential to regulate hypercholesterolemia.

Keywords: Policosanol, Low-density lipoprotein cholesterol, Triglyceride, Hypercholesterolemia, Cardiovascular disease

1. Introduction

Major prevention refers to the controlling of cardiovascular risk factors, such as increased LDL-C, in patients who have never had a coronary incident. Depending on population - based studies data showing a consistent, positive, and graded association between heart disease events and LDL-C density and death rates, it is believed that focusing on a major prevention of LDL lessening will minimize risk in both patient populations with and without cardiovascular illness at a wide array of concentrations (Reiter-Brennan et al., 2020; Ference et al., 2017; Virani et al., 2020).

Individuals lacking known cardiovascular illness often have considerably lower initial probabilities for cardiovascular risk than do those who have. The overall risk decrease from treating hypercholesterolemia would often be lower for individuals who already have cardiovascular disease (CVD), therefore the choice to prescribe LDL medication will rely on the overall CVD risk (Reiter-Brennan et al., 2020; Ference et al., 2017). Research findings with clinical end-points have shown a connection between cardiovascular events and high intensities of LDL-C and total cholesterol in serum (Ference et al., 2017), aside from the benefits of take down LDL-C (Arnett et al., 2019; Lloyd et al., 2013; Heart, 2002; Ford et al., 2016; Kim and Le, 2020; Kazi et al., 2017; Packard, 2015).

A group of long-chain aliphatic primary alcohols that were initially extracted from wax made from sugar cane (*Saccharum officinarum* L.) widely known as policosanol (RC) (Arruzazabala et al., 2000). Three substances make up the majority of the combination: octacosanol (60–70% by weight), triacontanol (10–20% by weight), and hexacosanol (4–10% by weight). Rice bran, wheat germ and bee wax are only a few examples of alternative natural materials from which the combination can be produced (Wang et al., 2003; Aleman et al., 2001), however the commercially available products predominantly comprise sugar cane policosanol (SCP). In fact, PC supplementation has been approved as a cholesterol-lowering product in several nations (Yanai et al., 2015), and SCP has been utilized in Cuba in a significant number of individuals for its cholesterol-lowering characteristics.

Policosanol has been shown to reduce lipid level in individuals suffering from type II hyperlipidemia (Canetti et al., 1997; Mas et al., 1999; Aneiros et al., 1995; Mas, 2000). Policosanol has other significant pleiotropic properties, which include the reduction of LDL

oxidation sensitivity and the prevention of platelet adhesion (Castaño et al., 2002; Menéndez et al., 2000; Arruzazabala et al., 1998). Policosanol has been shown in clinical tests to be both tolerable and safe (Fernández et al., 2004; Castaño et al., 2002; Menéndez et al., 2000; Arruzazabala et al., 1998; Canetti et al., 1997; Mas et al., 1999; Aneiros et al., 1995; Mas, 2000).

There is still more to learn about the mechanism underlying PC-induced cholesterol reduction. According to several studies, HMG-CoA, also known as 3-hydroxy-3methylglutaryl-coenzyme A, is the rate-limiting step in the production of cholesterol, appears to be less likely to be synthesized and more likely to be degraded as a result of PC (Kabir and Kimura, 1993; Menendez et al., 2001). Further research has shown that PC can reduce blood cholesterol by promoting AMP-kinase phosphorylation in mouse liver and hepatoma cell cultures (Singh and Poster, 2006; Banerjee et al., 2011). This clinical research was done to look into the safety and tolerability besides the efficacy of policosanol medication on the lipid panel in Korean persons.

2. Subjects and Methods

2.1. The ingredients of the test and placebo products

Table 1 lists the ingredients of the placebo and test products.

Article Error

2.2. Study population and design

The investigation was executed according to compliance with the ethical guidelines of the Helsinki Declaration (World Medical Association, 2013). The Wonkwang University Korean Medical Hospital's institutional review board (IRB) (Iksan, South Korea) examined and confirmed study procedures. To prepare medical staff to offer consistent intervention, all the investigators employed the same standardized protocols, written instructions, precise directions, and training materials. Throughout a training session for all the investigators, the protocol was taught, and the coordinating center addressed any issues that came up during the study follow-up. Prior to taking part in the trial, each participant signed an informed consent form.

The study's clinical trial registry number is IRB 2020-18. The study involved 80, 20 healthy male and female participants, aged 19 to 75 were divided into two groups for our 8-week, randomized, double-blind, placebo-controlled human trial of individuals with baseline

LDL-C (low-density lipoprotein cholesterol) concentrations of at least 100-159 mg/dL in the fasting blood test at the time of screening. According to protocol, 80 healthy volunteers were divided into two groups at random and given either policosanol (20 mg/day) or a placebo (both n = 40) for eight weeks. At day 0 and at the completion of the drug trial, lipid levels in serum were assessed.

2.3. Treatment and exclusion criteria

Test products were identical and labelled clearly before distribution. Treatment was randomly assigned using a 1:1 randomization ratio and a computer-generated random allocation scheme with balanced blocks. Test tablets were given once daily after a meal. Participants having triglyceride levels of 200 mg/dL or higher and total cholesterol levels of 240 mg/dL or higher in the fasting blood test at the time of screening were excluded from the experiment. Individuals were disqualified if they had severe kidney damage, a record of liver problems, a diagnosis of a tumor, were alcoholics, or suffered from chronic diseases. Additionally, individuals who had taken another lipid-lowering drug within six months prior to entering the study, those with a record of allergy to the wax alcohols of *Saccharum officinarum* (Policosanol), and those who had any additional particular circumstances that, in the doctor's opinion, would threaten their health and well-being during the clinical trial were also excluded. Additionally, the individuals were required to give specifics about their food intake and regular exercise at each visit (Kim et al., 2020; Kang et al., 2016; Nyambe-Silavwe and Williamson, 2016).

2.4. Assessments of safety and tolerability

In the safety analysis, everyone who was randomly assigned and subjected to minimum one study intervention dose was taken into account. Standard laboratory techniques employed at Precise Lab Solution (Jeonju, South Korea) to investigate hematocrit, hemoglobin, RBC, and, WBC were examined using standard laboratory protocols. Blood biochemistry includes leptin, adiponectin, creatinine, blood urea nitrogen (BUN), glucose, gamma-glutamyl transpeptidase (GGT), alanine aminotransferase (ALT), lactate dehydrogenase (LDH), aspartate aminotransferase (AST), creatine kinase (CK), total protein, albumin, total bilirubin, and alkaline phosphatase (ALP). Specific gravity and pH are included in the urine test. Vital signs including blood pressure, heart rate, and body

temperature were all measured as part of safety evaluations, and safety occurrences were tracked as well.

2.5. Statistical evaluation

Fisher's exact tests, independent t-tests, chi-square tests, and were utilized to contrast the initial traits of the placebo and test groups. An independent t-test was used to compare the two groups' anthropometric features including urinalysis, and blood biochemistry. The outcomes were displayed as mean \pm SD. P^{\pm} 0.05 was used as the significant level. The SAS computer program version 9.3 was used to carry out all statistical experiments (Cary, North Carolina, USA-based SAS Institute).

3. Results

The consort flow chart (Figure 1) presents information about the subject's disposition. 25 males (15 randomly assigned to policosanol, 10 to a placebo) and 55 women (25 randomly assigned to policosanol, 30 to a placebo) were included in the study. Two trial subjects from the policosanol group and two from the placebo group withdrew due to pregnancy; this was not related to any adverse effects. The fact that the majority of the features were the same in both groups indicates that randomization was successful because the beginning characteristics of the two groups did not significantly differ from one another (Table 2).

3.1. Primary outcome

After 8 weeks, the LDL-C concentration was considerably lesser in the policosanol group in comparison to the placebo group. According to the statistical examination, level of LDL-C was $-4.87 \pm 11.30 \text{ mg/dL}$ lower in policosanol batch at 8 weeks than they were interesting placebo batch (p = 0.014). The concentration of total cholesterol in the placebo batch and the policosanol batch were noticeably different after 8 weeks. The statistical study indicates that the total cholesterol concentrations were $-6.82 \pm 14.32 \text{ mg/dL}$ after 8 weeks, they were lowered in the policosanol proup versus the placebo group (p = 0.007). Compared to the group receiving a placebo, where triglyceride levels rose, the policosanol group had a drop in triglyceride levels. At week 8, there was a mean change of -9.37 ± 19.27 mg/dL in the policosanol group, compared to 5.33 ± 27.25 mg/dL in placebo batch (p = 0.008). Compared to the placebo group, the HDL-C levels increased in the policosanol group. At week 8, the mean change in the policosanol group was $3.50 \pm 55 \text{ mg/dL}$, compared to $0.26 \pm 0.09 \text{ mg/dL}$ in the placebo group (p = 0.010). While non-HDL-C levels rose in the placebo group, they

decreased in the policosanol group. At week 8, the mean decrease in the policosanol group was $-10.32 \pm 13.75 \text{ mg/dL}$, as opposed to $0.56 \pm 7.88 \text{ mg/dL}$ as respect to the placebo group (p = 0.0001) (Table 3).

3.2. Secondary outcome

Table 4 shows the impact of policosanol on atherogenic parameters in serum; policosanol administration resulted in a decrease in serum T-cholesterol-HDL-C/HDL-C ratio (-0.33 (SD 0.33) v. 0.00 (SD 0.31), p = 0.0001), triglyceride/HDL-C ratio (-0.28 (SD 0.40) v. 0.09 (SD 0.57), p = 0.001) LDL-C/HDL-C ratio (-0.21 (SD 0.27) v. 0.00 (SD 0.21), p = 0.0002), and total cholesterol/HDL-C ratio (-0.33 (SD 0.33) v. 0.00 (SD 0.31), p = 0.0001) when compared to placebo values.

3.3. Safety parameters

Without experiencing any negative or adverse reactions, all subjects finished the protocol. Neither of the groups experienced any subject complaints. The biochemistry of the blood (creatinine, BUN, glucose, GGT, LD, ALT, AST, CK, ALP, total bilirubin, albumin, total proteins), CBC (WBC, RBC, hemoglobin, hematocrit, platelets count), and urinalysis (specific gravity, pH) did not alter significantly after the 8-week experiment (Table 5).

4. Discussion

Controlling the blood's level of cholesterol is the therapeutic objective for treating hyperlipidemia and the CVD it causes. The blood LDL, and TG levels are reduced while HDL levels are raised in order to control cholesterol. For managing cholesterol, there are already drugs accessible, however, the patient may suffer from the adverse effects and expenses of taking them. The statin-induced myopathies are the most common adverse effects (AE) with statins, which were initially obtained from fungus (Azemawah et al., 2019). Nausea, discomfort, cholelithiasis, cholecystitis, hepatic problems, and coagulation abnormalities are among the adverse events (AE) associated with fibrates, a different family of medication used to treat hyperlipidemia (Okopień et al., 2018). Despite these findings, a natural remedy could be a less expensive option with fewer and milder side effects than current drugs,

This randomized clinical trial examined the impact of policosanol on individuals' serum lipid levels. According to the latest findings, 8 weeks of policosanol use significantly decreased TG, TC, and LDL-C levels while concurrently raising HDL-C levels and

significantly lowering the ratios of total cholesterol to HDL, LDL-C to HDL, triglycerides to HDL, and T-cholesterol to HDL-C. Prior research provided the findings of a randomized, double-blind, placebo-controlled investigation on the effects of policosanol on elderly adults with type II hyperlipidemia. Considering the total cholesterol findings (6.1 mmol/L), the participants took 5–10 mg of policosanol each day for a year. In the long run, the policosanol therapy group considerably reduced the LDL/HDL-C ratio (22.2%), TG (11.9%), TC (15.4%), ^{5p.} and LDL-C (20.5%), while increasing HDL-C by as much as 12.7% (Castaño et al., 2002).

Furthermore, policosanol showed both efficiency and tolerance in individuals with high global cardiovascular risk, resulting in a marked decline in serum LDL-C/HDL-C, TC/HDL-C, TG, TC, and LDL-C as well as an increase in HDL-C. No drug-related adverse clinical or biochemical consequences were seen after the effective course of treatment (Castaño et al., 1999). Uncertainty exists regarding the precise molecular pathways by which policosanol lowers lipid levels. However, other investigations have determined that the activity of policosanol involves a variety of mechanisms, involving the activation of AMPkinase, the inhibition of cholesteryl ester transfer protein, and the suppression of HMG-CoA reductase (Kim et al., 2017; Singh et al., 2006; Mccarty, 2002).

There is presently no supplement that has been shown to be both secure and successful in controlling hyperlipidemia. In the current trial, we demonstrate the safety and efficacy of policosanol in the regulation of hyperlipidemia. Policosanol intake boosted HDL and decreased blood levels of LDL, TG, and TC. This study also demonstrated the safety of taking policosanol supplements, as there were no significant negative side effects. Furthermore, policosanol can be regarded as secure and useful in assisting individuals in controlling their blood cholesterol. The study showed policosanol, a natural wax, helped control cholesterol levels by regulating lipid markers. For individuals with mild to severe hypercholesterolemia, policosanol is a safe and effective therapeutic choice because it had no harmful effects on the individuals' physiological parameters and did not change their health status.

5. Conclusion

There were some limitations to the current investigation. To begin with, 80 participants participated in the study. To come to a firmer conclusion about policosanol efficacy, it would be beneficial to carry out a follow-up study with a bigger sample size and in more than one location. In addition, our study lasted for 8 weeks only. To get to a firmer conclusion regarding policosanol tong-term efficiency, it could be beneficial to conduct research over a longer period of time.

Revised Manuscript 3

ORIGINALITY REPORT


ORIGIN	ALITY REPORT				
SIMILA	4%	10% INTERNET SOURCES	10% PUBLICATIONS	2% STUDENT P	APERS
PRIMAR	Y SOURCES				
1	WWW.NC	bi.nlm.nih.gov			2%
2	as Biom	lyun Cho. "High arkers and Ther r Science and Bu	rapeutic Tools	11 7	1 %
3	summit.				1%
4		EJ. "Orlistat", The on, 1/1/2004	e Journal of Dr	ſug	1 %
5	WWW.jst	age.jst.go.jp			1%
6	www.ph	iladelphia.edu.j	0		1 %
7	Park, Jae Term Co	ng Kim, Dhanan e-Ryong Kim, Ky onsumption of C Central and Bra	ung-Hyun Cho Luban Policosa	o. "Long- anol	1 %

and Improves Lipid Profile With Enhancement of Lipoprotein Properties in Healthy Korean Participants", Frontiers in Physiology, 2018

Publication

8	res.mdpi.com Internet Source	1 %
9	repository-tnmgrmu.ac.in	1%
10	ash.silverchair-cdn.com	1 %
11	researchportal.hkr.se	<1%
12	www.mediworks.ca	<1%
13	docksci.com Internet Source	<1%
14	Parviz Khajehdehi. "Effect of Vitamins on the Lipid Profile of Patients on Regular Hemodialysis", Scandinavian Journal of Urology and Nephrology, 2009 Publication	<1%
15	arizona.openrepository.com	<1%
16	jurnal.ugm.ac.id Internet Source	<1%


17	rcastoragev2.blob.core.windows.net	<1%
18	www.mdpi.com	<1%
19	WWW.Science.gov Internet Source	<1%
20	WWW.e-sc.org Internet Source	<1%
21	Chao Han, Tao Wang, Hong-qiang Jiang, Jian- xiong Ma, Peng Tian, Jia-cheng Zang, Xin-long Ma. "An Animal Model of Modic Changes by Embedding Autogenous Nucleus Pulposus inside Subchondral Bone of Lumbar Vertebrae", Scientific Reports, 2016 Publication	<1%
22	ijpr.sbmu.ac.ir Internet Source	<1%
23	jifro.ir Internet Source	<1 %
24	worldwidescience.org	<1%
25	"EUROANAESTHESIA 2005: Annual Meeting of the European Society of Anaesthesiology Vienna, Austria, May 28–31, 2005", European Journal of Anaesthesiology, 09/14/2005 Publication	<1%



Exclude quotes	Off	Exclude matches	Off
Exclude bibliography	Off		

Revised Manuscript 3

PAGE 1	
ETS	Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.
ETS	Wrong Article You may have used the wrong article or pronoun. Proofread the sentence to make sure that the article or pronoun agrees with the word it describes.
ETS	Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.
ETS	Wrong Article You may have used the wrong article or pronoun. Proofread the sentence to make sure that the article or pronoun agrees with the word it describes.
ETS	Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.
ETS	Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.
PAGE 2	
(ETS)	Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.
ETS	Sentence Cap. Review the rules for capitalization.
(ETS)	Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.
ETS	Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.
ETS	Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.
ETS	Missing "," Review the rules for using punctuation marks.
ETS?	Article Error You may need to remove this article.
ETS	Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.





Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.



Article Error You may need to remove this article.



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.




Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.

PAGE 6


ETS

ETS

ETS




Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.





(ETS) Article Error You may need to use an article before this word.


- (ETS) Article Error You may need to use an article before this word.
 - **Sp.** This word is misspelled. Use a dictionary or spellchecker when you proofread your work.





PAGE 7

(ETS



Sp. This word is misspelled. Use a dictionary or spellchecker when you proofread your work.